

Cardiovascular and Interventional Radiological Society of Europe

GEST 2017

E U R O P E



**Global Embolization
Symposium and Technologies**

Preliminary Programme

**May 31 – June 03
Florence, Italy**

www.gest2017.eu

CIRSE *foundation*

1	Welcome Address / Scientific Programme Committee
2	Scientific Programme Overview
4	Scientific Programme
14	Faculty List
15	General Information
16	Accommodation
17	City Map / List of Hotels



The Preliminary Programme GEST Europe 2017

In case of any enquiries or comments, please contact us at office@esir.org.

© CIRSE Foundation / 2016

Graphic Design:

LOOP. ENTERPRISES media
www.loop-enterprises.com

The CIRSE Foundation does not accept responsibility for errors or misprints.

Dear Colleagues,

Embolisation is not only an established technique in the IR's repertoire – this versatile therapy is developing at an exciting rate and embracing many new clinical applications. Embolotherapy has long since played a vital role in the treatment of GI bleeding and AVMs, and new techniques are allowing interventionalists to branch out even further, with novel treatments for prostate hyperplasia, obesity and haemorrhoids currently being investigated.

The GEST Europe programme for 2017 has been meticulously designed, and it certainly reflects this growth and versatility, with sessions planned on coils and plugs, trauma management, vascular and lymphatic malformations, a focus on the chest area, fibroid treatment, liver embolotherapies, as well as the latest embolics and much more!

Alongside plenary and parallel sessions, there will also be hands-on workshops on coils and plugs, liquid embolics, particles and gelfoam, plus a range of clinical case-based discussions.

Since its official creation, the biennial GEST Europe meeting has positioned itself as one of the leading embolotherapy congresses. In 2015, over a thousand participants from around the world joined us in the beautiful Spanish city of Seville for another dynamic meeting.

GEST Europe 2017 will take place in Florence, Italy from May 31 – June 3, and is certain to be another great opportunity to discover the latest advances in embolotherapy.

We look forward to seeing you there!

Scientific Programme Committee



A.-M. Belli



C.A. Binkert



M.D. Darcy



F. Fanelli



J. Golzarian



Z.J. Haskal



R.A. Morgan



C.E. Ray Jr



M.R. Sapoval



D.Y. Sze


Wednesday, May 31

Thursday, June 1

08:00							08:00
15							15
30							30
45							45
09:00	101 Coils and plugs			701 Liquid embolic agents	702 Fibroid embolisation		09:00
15							15
30							30
45							45
10:00	Break			Break			10:00
15							15
30							30
45							45
11:00	201 Trauma	202 HCC		801 Vascular and lymphatic malformations	802 GI haemorrhage		11:00
15							15
30							30
45							45
12:00	Break			Break			12:00
15							15
30							30
45							45
13:00	Satellite Symposia			Satellite Symposia			13:00
15							15
30							30
45							45
14:00	Break			Break			14:00
15							15
30							30
45							45
15:00	401 Imaging	402 Radioembolisation dose calculation, mapping and follow-up	HoW 1 Coils and plugs	1001 Chest	1002 Management of complex visceral aneurysms	HoW 4 Liquid embolics	15:00
15							15
30							30
45							45
16:00	Break			Break			16:00
15							15
30							30
45							45
17:00	501 GU embolisation	502 Management of complex HCC	HoW 2 Coils and plugs	1101 Abdominal embolisation	1102 Management of complex AVM	HoW 5 Liquid embolics	17:00
15							15
30							30
45							45
18:00	Break			Break			18:00
15							15
30							30
45							45
19:00	Satellite Symposium			Satellite Symposium			19:00

Friday, June 2

Saturday, June 3



Scientific Programme

Wednesday, May 31

08:00-09:45

Plenary Session

101 Coils and Plugs

- 101.1 Catheter choice for delivery of plugs and coils
O.M. van Delden (Amsterdam/NL)
- 101.2 Techniques for coil deployment
G. Maleux (Leuven/BE)
- 101.3 When to stop: endpoints for mechanical embolisation
K. Osuga (Osaka/JIP)
- 101.4 Technical differences between coils: density, fibres and hydrogel
D. Vorwerk (Ingolstadt/DE)
- 101.5 Plugs and microplugs: update
M.A. Ruffino (Turin/IT)
- 101.6 Coils, plugs or both: when and why
B. Arslan (Chicago, IL/US)
- 101.7 Complications using coils and plugs: how to avoid and how to solve!
O.M. van Delden (Amsterdam/NL)
- 101.8 Debate – Detachable coils: pro
J.-P. Pelage (Caen/FR)
- 101.9 Debate – Detachable coils: con
M.S. Johnson (Indianapolis, IN/US)
- 101.10 Advanced clinical cases
J.F. Benenati (Miami, FL/US)
- 101.11 Advanced clinical cases
D. Vorwerk (Ingolstadt/DE)

Discussion

10:15-12:00

Parallel Session

201 Trauma

- 201.1 Management algorithms for trauma
M.D. Darcy (St. Louis, MO/US)
- 201.2 Splenic embolisation: proximal vs. distal embolisation
R. Uberoi (Oxford/GB)
- 201.3 Hepatic trauma embolisation: how to minimise complications
M. Cariatì (Milan/IT)
- 201.4 Blunt and penetrating renal trauma: when and how to embolise
P.P. Goffette (Brussels/BE)
- 201.5 Embolisation of pelvic trauma: technique and outcomes
M.S. Hamady (London/GB)
- 201.6 Endovascular management for iatrogenic non-visceral injuries
R. Uberoi (Oxford/GB)
- 201.7 Endovascular management of extremity trauma
M. Cariatì (Milan/IT)
- 201.8 Endovascular management of aortic trauma
H. Rousseau (Toulouse/FR)
- 201.9 Endovascular management of head and neck trauma
L. Defreyne (Ghent/BE)
- 201.10 Debate – Empiric embolisation for pelvic trauma: safe and indicated
O.M. van Delden (Amsterdam/NL)
- 201.11 Debate – Empiric embolisation for pelvic trauma: increases complications
W.E. Saad (Ann Arbor, MI/US)

Discussion

10:15-12:00

Parallel Session**202 HCC**

- 202.1 Patient assessment before IR treatment
R. Lencioni (Miami, FL/US)
- 202.2 Basics of radioembolisation dosimetry
T.F. Jakobs (Munich/DE)
- 202.3 Results of conventional TACE
G. Mauri (San Donato Milanese/IT)
- 202.4 Results of drug-eluting TACE
K. Malagari (Athens/GR)
- 202.5 HCC with portal vein occlusion TARE or TACE
R.J. Lewandowski (Chicago, IL/US)
- 202.6 Radiation segmentectomy and/or lobectomy
R.J. Lewandowski (Chicago, IL/US)
- 202.7 Matching therapy to patient
M. Grosso (Cuneo/IT)
- 202.8 Downstaging and bridging to transplantation
C.E. Ray, Jr. (Chicago, IL/US)
- 202.9 Debate – Is there a role for embolisation pre TARE: pro
K. Ahrar (Houston, TX/US)
- 202.10 Debate – Is there a role for embolisation pre TARE: con
P.L. Pereira (Heilbronn/DE)
- 202.11 Alternative chemotherapeutic agents for TACE
Y. Arai (Tokyo/JP)
- 202.12 Anti-reflux or flow arrest for TACE
S. Miyayama (Fukui/JP)

Discussion

14:00-15:00

Hands-on Workshop**HoW 1 Coils and plugs**

For further information please visit www.gest2017.eu.

14:15-15:45

Parallel Session**401 Imaging**

- 401.1 New guidance tool for liver embolisation
B.C. Meyer (Hannover/DE)
- 401.2 Practical aspects of live image guidance during embolisation procedures
H. Kobeiter (Créteil/FR)
- 401.3 CBCT in liver embolisation: optimising parameters
D.Y. Sze (Stanford, CA/US)
- 401.4 Use of advanced planning & guidance software for complex liver tumour embolisation
T. de Baère (Villejuif/FR)
- 401.5 Role of US in the angio suite for defining the right target for TACE/TAE
F. Orsi (Milan/IT)
- 401.6 Fusion imaging: how to use it to optimise embolisation
B.C. Meyer (Hannover/DE)
- 401.7 Can CBCT flow and perfusion provide endpoints for tumour embolisation
O. Pellerin (Paris/FR)
- 401.8 CBCT: how much is the radiation load to the patient
H. Kobeiter (Créteil/FR)

Discussion

14:15-15:15

Clinical Case-Based Discussion**402 Radioembolisation dose calculation, mapping and follow-up**402.1 *G. Maleux (Leuven/BE)*402.2 *M. Grosso (Cuneo/IT)*

15:15-16:15

Clinical Case-Based Discussion**403 Embolisation of bronchial and pulmonary artery**403.1 *R. Loffroy (Dijon/FR)*403.2 *J. Pollak (New Haven, CT/US)*

15:30-16:30

Hands-on Workshop**HoW 2 Coils and plugs**

For further information please
visit www.gest2017.eu

16:15-17:45

Parallel Session**501 GU embolisation**

501.1 Varicocele embolisation: technique

P. Haage (Wuppertal/DE)

501.2 Varicocele embolisation and fertility: results

L. Machan (Vancouver/CA)

501.3 Embolisation of angiomyolipomas: technique and outcomes

L.B. Lönn (Copenhagen/DK)

501.4 Embolisation in polycystic kidney disease for volume reduction

to be announced

501.5 Renal embolisation to destroy residual renal function

to be announced

501.6 Embolisation in priapism

N. McEniff (Dublin/IE)

501.7 Embolotherapy of haematuria of non-renal origin

L.B. Lönn (Copenhagen/DK)

501.8 PAE for prostate cancer: early experience

T. Bilhim (Lisbon/PT)

501.9 Non-vascular embolisation for urological problems

Y. Arai (Tokyo/JP)

Discussion

16:15-17:15

Clinical Case-Based Discussion**502 Management of complex HCC**502.1 *K. Malagari (Athens/GR)*502.2 *F. Orsi (Milan/IT)*

17:00-18:00

Hands-on Workshop**HoW 3 Coils and plugs**

For further information please
visit www.gest2017.eu

Thursday, June 1

08:00-09:45

Parallel Session**701 Liquid embolic agents**

- 701.1 Principles and comparison of liquid agents
D. Savio (Turin/IT)
- 701.2 Glue: preparations and formulations
Y. Arai (Tokyo/JP)
- 701.3 Onyx vs. Squid vs. Phil
R. Loffroy (Dijon/FR)
- 701.4 Sclerosing agents and foam: agent selection and technical tips
M. Grosso (Cuneo/IT)
- 701.5 Tips and tricks for non-sclerosing liquid agents
L. Defreyne (Ghent/BE)
- 701.6 Tips and tricks for sclerosing liquid agents
D.Y. Sze (Stanford, CA/US)
- 701.7 Ethiodised oils (Lipiodol): more than an embolic transporter
S. Miyayama (Fukui/JP)
- 701.8 When to stop: endpoints and how to avoid complications
F. Fanelli (Rome/IT)
- 701.9 Debate – If I could only have one, I would use glue
V. Vidal (Marseille/FR)
- 701.10 Debate – If I could only have one, I would use EVOH-based agents
L. Defreyne (Ghent/BE)
- 701.11 Advanced clinical cases
Y. Arai (Tokyo/JP)
- 701.12 Advanced clinical cases
D. Savio (Turin/IT)

Discussion

08:00-09:45

Parallel Session**702 Fibroid embolisation**

- 702.1 New developments in the medical management of fibroids
P.N.M. Lohle (Tilburg/NL)
- 702.2 Embolic agents for UAE: systematic review
R. Das (London/GB)
- 702.3 Embolisation specific endpoints for different agents
J.B. Spies (Washington, DC/US)
- 702.4 Embolisation of non-uterine collaterals
P.N.M. Lohle (Tilburg/NL)
- 702.5 Guidelines of fibroid embolisation: international perspective
M. Sone (Tokyo/JP)
- 702.6 UFE and fertility update
J.-P. Pelage (Caen/FR)
- 702.7 Clinical role of IR in UFE
A.-M. Belli (London/GB)
- 702.8 Peri-procedural pain reduction: blocks, epidurals, sedation and alternative medicine
C.A. Binkert (Winterthur/CH)
- 702.9 Complications: how to minimise and manage
T.J. Kroencke (Augsburg/DE)
- 702.10 Advanced clinical cases
F. Orsi (Milan/IT)
- 702.11 Advanced clinical cases
R. Das (London/GB)

Discussion

10:15-12:00

Parallel Session**801 Vascular and lymphatic malformations**

- 801.1 Vascular malformations: diagnosis and classification
W.A. Wohlgemuth (Regensburg/DE)
- 801.2 Which agents to use in malformations: low flow
P. Rowlands (Liverpool/GB)
- 801.3 Sclerotherapy technique, outcome and complications: low flow
M.-F. Giroux (Montreal/CA)
- 801.4 Which agents to use in malformations: high flow
J.A. Reekers (Amsterdam/NL)
- 801.5 Technique, outcome and complications: high flow
P. Rowlands (Liverpool/GB)
- 801.6 AVMs: embolising the arterialised veins
Y.-S. Do (Seoul/KR)
- 801.7 Advances in the use of dilute alcohol in AVMs
Y.-S. Do (Seoul/KR)
- 801.8 Management of renal AVMs
M.-F. Giroux (Montreal/CA)
- 801.9 Clinical and imaging follow-up after treatment
P. Haage (Wuppertal/DE)
- 801.10 Debate – High flow AVMs should be treated from a venous approach: pro
I. McCafferty (Birmingham/GB)
- 801.11 Debate – High flow AVMs should be treated from a venous approach: con
J.A. Reekers (Amsterdam/NL)
- 801.12 Advanced clinical cases
W.E. Saad (Ann Arbor, MI/US)
- 801.13 Advanced clinical cases
P. Rowlands (Liverpool/GB)

Discussion

10:15-12:00

Parallel Session**802 GI haemorrhage**

- 802.1 Management algorithms for upper and lower GI haemorrhage
R. Uberoi (Oxford/GB)
- 802.2 Optimisation of angiographic technique and provocative manoeuvres
B.S. Funaki (Chicago, IL/US)
- 802.3 Safety and efficacy of embolisation for upper GI haemorrhage
P.P. Goffette (Brussels/BE)
- 802.4 Embolisation technique: how distal
G. Carrafiello (Varese/IT)
- 802.5 Safety and efficacy of embolisation for lower GI haemorrhage
R.C. Gaba (Chicago, IL/US)
- 802.6 Is there a role for empiric embolisation in the upper and lower GI tract?
N. McEniff (Dublin/IE)
- 802.7 Embolisation and stent grafts for post GI surgery bleeding
M.R. Sapoval (Paris/FR)
- 802.8 Technique and results of embolisation in haemorrhoids
V. Vidal (Marseille/FR)
- 802.9 Debate – Is there a role for liquid embolic agents: pro
F. Fanelli (Rome/IT)
- 802.10 Debate – Is there a role for liquid embolic agents: con
B.S. Funaki (Chicago, IL/US)

Discussion

14:00-15:00

Hands-on Workshop**HoW 4 Liquid embolics**

For further information please
visit www.gest2017.eu

14:15-15:45

Parallel Session**1001 Chest**

- 1001.1 Clinical and imaging workup for haemoptysis
G. Carrafiello (Varese/IT)
- 1001.2 Arterial anatomy and variants for haemoptysis
J. Pollak (New Haven, CT/US)
- 1001.3 Bronchial artery embolisation: long-term outcome and management of recurrence
R. Niola (Naples/IT)
- 1001.4 Bronchial artery embolisation: how to avoid complications
M.-F. Carette (Paris/FR)
- 1001.5 Debate – Liquids should replace particles in bronchial artery embolisation: pro
R. Loffroy (Dijon/FR)
- 1001.6 Debate – Liquids should replace particles in bronchial artery embolisation: con
T. Tanaka (Kashihara/JP)
- 1001.7 Pulmonary AVM: choice of materials and technical tips
J. Pollak (New Haven, CT/US)
- 1001.8 Endovascular management of pulmonary artery pseudoaneurysms
M.-F. Carette (Paris/FR)
- 1001.9 Intrnodal lymphangiography and thoracic duct embolisation: technical TIPS
R.C. Gaba (Chicago, IL/US)
- 1001.10 Results of thoracic duct embolisation
R.C. Gaba (Chicago, IL/US)

Discussion

14:15-15:15

Clinical Case-Based Discussion**1002 Management of complex visceral aneurysms**

- 1002.1 *M. Szczerbo-Trojanowska (Lublin/PL)*
- 1002.2 *M.S. Hamady (London/GB)*

15:15-16:15

Clinical Case-Based Discussion**1003 Varicoceles and pelvic congestion**

- 1003.1 *T. Jargiello (Lublin/PL)*
- 1003.2 *L. Machan (Vancouver/CA)*

15:30-16:30

Hands-on Workshop**HoW 5 Liquid embolics**

For further information please visit
www.gest2017.eu

16:15-17:45

Parallel Session**1101 Abdominal embolisation**

- 1101.1 Embolisation/ablation of benign liver lesions
K. Ahrar (Houston, TX/US)
- 1101.2 Embolisation for hypersplenism and thrombocytopaenia
M. Szczerbo-Trojanowska (Lublin/PL)
- 1101.3 Gastric artery embolisation: update of results and future directions
A. Arepally (Atlanta, GA/US)
- 1101.4 Transarterial therapy for pancreatic cancer
T. Tanaka (Kashihara/JP)
- 1101.5 Bleeding post-pancreatic transplant
J.F. Angle (Charlottesville, VA/US)
- 1101.6 Durable means to occlude the bile duct
E. Brountzos (Athens/GR)
- 1101.7 Embolisation for retroperitoneal and spontaneous abdominal wall haemorrhage
A. Krajina (Hradec Králové/CZ)
- 1101.8 Interventional management of haemobilia
K.A. Hausegger (Klagenfurt/AT)
- 1101.9 Management of GI fistulae
Z.J. Haskal (Charlottesville, VA/US)

Discussion

16:15-17:15

Clinical Case-Based Discussion**1102 Management of complex AVM**

- 1102.1 *I. McCafferty (Birmingham/GB)*
- 1102.2 *W.A. Wohlgemuth (Regensburg/DE)*

17:00-18:00

Hands-on Workshop**HoW 6 Liquid embolics**

For further information please visit
www.gest2017.eu

Friday, June 2

08:00-09:45

Parallel Session**1301 Particles and gelfoam**

- 1301.1 Particles and gelfoam: indications and choice of agents
D. Vorwerk (Ingolstadt/DE)
- 1301.2 Microparticles: what do we need to know
K. Osuga (Osaka/JP)
- 1301.3 When to stop: endpoints for particulate embolisation
R. Niola (Naples/IT)
- 1301.4 5 top tips and tricks using gelfoam
M. Sone (Tokyo/JP)
- 1301.5 5 top tips and tricks using particles
J.B. Spies (Washington, DC/US)
- 1301.6 Drug-eluting particles: characteristics
K. Malagari (Athens/GR)
- 1301.7 Complications using particles and gelfoam: how to avoid and how to solve!
H.T. Abada (Abu Dhabi/AE)
- 1301.8 Particles for embolisation: new development and future
J. Golzarian (Minneapolis, MN/US)
- 1301.9 Debate – Resorbable particles will replace non-resorbable particles: pro
A. Arepally (Atlanta, GA/US)
- 1301.10 Debate – Resorbable particles will replace non-resorbable particles: con
T.J. Kroencke (Augsburg/DE)
- 1301.11 Advanced clinical cases
K. Osuga (Osaka/JP)
- 1301.12 Advanced clinical cases
H. Kobeiter (Créteil/FR)

Discussion

08:00-09:45

Parallel Session**1302 Portal hypertension and portal venous embolisation**

- 1302.1 Indications for RTO and/or TIPS
G. Maleux (Leuven/BE)
- 1302.2 Classic BRTO: anatomy and results
B. Arslan (Chicago, IL/US)
- 1302.3 PARTO: technique and results
D.I. Gwon (Seoul/KR)
- 1302.4 BRTO variants: ATOs and ARTOs
H. Kiyosue (Yufu/JP)
- 1302.5 Treatment of ectopic varices
R.C. Gaba (Chicago, IL/US)
- 1302.6 Transsplenic approaches to variceal embolisation
W.E. Saad (Ann Arbor, MI/US)
- 1302.7 Debate – Embolisation of portal venous varices during TIPS: pro
A. Krajina (Hradec Králové/CZ)
- 1302.8 Debate – Embolisation of portal venous varices during TIPS: con
H. Rousseau (Toulouse/FR)
- 1302.9 Splenic artery embolisation in patients with portal hypertension
S. Bhatia (Davie, FL/US)
- 1302.10 Principles and indications for portal venous embolisation
E. Brountzos (Athens/GR)
- 1302.11 Transarterial radioembolisation as an alternative to portal vein embolisation
R.J. Lewandowski (Chicago, IL/US)
- 1302.12 Advanced clinical cases
A.M. Ierardi (Varese/IT)
- 1302.13 Advanced clinical cases
D.I. Gwon (Seoul/KR)

Discussion

10:15-12:00

Parallel Session**1401 Prostate artery embolisation**

- 1401.1 Current medical and surgical therapy: advantages and disadvantages
R. Das (London/GB)
- 1401.2 Patient evaluation and workup
N. Hacking (Southampton/GB)
- 1401.3 Prostate artery anatomy
T. Bilhim (Lisbon/PT)
- 1401.4 Step-by-step guide through PAE
F.C. Carnevale (São Paulo/BR)
- 1401.5 Optimising CBCT during PAE
M.R. Sapoval (Paris/FR)
- 1401.6 Selection of embolic agents for PAE
J. Golzarian (Minneapolis, MN/US)
- 1401.7 Clinical management and complications after PAE
N. Hacking (Southampton/GB)
- 1401.8 Debate – PAE is ready for wide-spread clinical adoption: pro
J.M. Pisco (Lisbon/PT)
- 1401.9 Debate – PAE is ready for wide-spread clinical adoption: con
J.B. Spies (Washington, DC/US)
- 1401.10 Meta-analysis and systematic review of results of PAE
Z.J. Haskal (Charlottesville, VA/US)
- 1401.11 PAE – future directions
M.R. Sapoval (Paris/FR)

Discussion

10:15-12:00

Parallel Session**1402 Endoleaks**

- 1402.1 Definitions, frequency and natural history of endoleaks
J.F. Benenati (Miami, FL/US)
- 1402.2 Is there a role for prophylactic embolisation to prevent endoleaks?
M.D. Dake (Stanford, CA/US)
- 1402.3 Cone-beam CT for direct sac embolisation
O. Pellerin (Paris/FR)
- 1402.4 Embolisation techniques for type 1
R.A. Morgan (London/GB)
- 1402.5 Embolisation techniques for type 2
A. Chavan (Oldenburg/DE)
- 1402.6 Transcaval approach: a valid technique for type 2?
J.F. Angle (Charlottesville, VA/US)
- 1402.7 Embolisation in TEVAR
M.D. Dake (Stanford, CA/US)
- 1402.8 Imaging follow-up after embolisation
R. Iezzi (Rome/IT)
- 1402.9 Complications and outcomes
A. Chavan (Oldenburg/DE)
- 1402.10 Advanced clinical cases
R.A. Morgan (London/GB)
- 1402.11 Advanced clinical cases
R. Iezzi (Rome/IT)

Discussion

14:00-15:00

Hands-on Workshop**HoW 7 Particles and gelfoam**

For further information please
visit www.gest2017.eu

14:15-15:45

Parallel Session**1601 Visceral aneurysms**

- 1601.1 Epidemiology and treatment indications
K.A. Hausegger (Klagenfurt/AT)
- 1601.2 Hepatic and splenic artery aneurysms:
embolisation techniques
J. Golzarian (Minneapolis, MN/US)
- 1601.3 Hepatic and splenic artery aneurysms: outcomes
and complications
A.M. Ierardi (Varese/IT)
- 1601.4 Renal artery aneurysms: technique and outcomes
M. Szczerbo-Trojanowska (Lublin/PL)
- 1601.5 Management of pseudoaneurysm secondary to
pancreatitis
M.-F. Giroux (Montreal/CA)
- 1601.6 Coeliac and SMA aneurysm: technique and
outcomes
M.S. Hamady (London/GB)
- 1601.7 Imaging follow-up
R.A. Morgan (London/GB)
- 1601.8 Debate – Keeping the parent artery open: pro
A.M. Ierardi (Varese/IT)
- 1601.9 Debate – Keeping the parent artery open: con
J.F. Benenati (Miami, FL/US)

Discussion

14:15-15:15

Clinical Case-Based Discussion**1602 Complex UFE**

- 1602.1 *M. Sone (Tokyo/JP)*
- 1602.2 *J.M. Pisco (Lisbon/PT)*

15:15-16:15

Clinical Case-Based Discussion**1603 Prostate artery anatomy**

- 1603.1 *S. Bhatia (Davie, FL/US)*
- 1603.2 *F.C. Carnevale (São Paulo/BR)*

15:30-16:30

Hands-on Workshop**HoW 8 Particles and gelfoam**

For further information please
visit www.gest2017.eu

16:15-17:45

Parallel Session**1701 Women's health**

- 1701.1 IR techniques in the management of morbidly
adherent placenta
L.B. Lönn (Copenhagen/DK)
- 1701.2 Debate – Prophylactic embolisation before
delivery: pro
F. Giurazza (Rome/IT)
- 1701.3 Debate – Prophylactic embolisation before
delivery: con
A.-M. Belli (London/GB)
- 1701.4 PPH: when and how
J.-P. Pelage (Caen/FR)
- 1701.5 Complications of embolisation for PPH
T.J. Kroencke (Augsburg/DE)
- 1701.6 Embolisation of uterine AVMs
F. Giurazza (Rome/IT)
- 1701.7 Embolisation technique and results for
adenomyosis
N. Hacking (Southampton/GB)
- 1701.8 Embolisation technique in pelvic congestion
syndrome
T. Jargiello (Lublin/PL)
- 1701.9 Management of perineal varicosities
A. Lopez (Guildford/GB)

Discussion

16:15-17:15

Clinical Case-Based Discussion**1702 Solid organ trauma**

- 1702.1 *H.T. Abada (Abu Dhabi/AE)*
- 1702.2 *J.F. Angle (Charlottesville, VA/US)*

Saturday, June 3

08:00-09:45

1901 Morbidity and Mortality

Coordinators:

F. Fanelli (Rome/IT), M.R. Sapoval (Paris/FR)

10:15-12:00

Parallel Session**2001 Embolisation of liver metastatic cancer and cholangiocarcinoma**

- 2001.1 When should embolisation be considered for colorectal liver mets?
A. Denys (Lausanne/CH)
- 2001.2 Irinotecan eluting particles for colorectal metastases: is there a role?
T.F. Jakobs (Munich/DE)
- 2001.3 Radioembolisation for colorectal carcinoma: results
M.S. Johnson (Indianapolis, IN/US)
- 2001.4 Lipiodol TACE for colorectal metastases: is there a role?
R. Lencioni (Miami, FL/US)
- 2001.5 Managing peri-procedural systemic therapy: whether to stop or continue in colorectal patients
G. Mauri (San Donato Milanese/IT)
- 2001.6 SIRFLOX trial: impact on treatment algorithm
A. Denys (Lausanne/CH)
- 2001.7 When should embolisation be considered for neuroendocrine tumours
T. de Baère (Villejuif/FR)
- 2001.8 Chemoembolisation and bland embolisation for neuroendocrine tumours
K. Ahrar (Houston, TX/US)
- 2001.9 TARE for neuroendocrine tumours
T.F. Jakobs (Munich/DE)
- 2001.10 When should embolisation be considered for cholangiocarcinoma
C.E. Ray, Jr. (Chicago, IL/US)
- 2001.11 Embolisation for cholangiocarcinoma: techniques and results
R. Lencioni (Miami, FL/US)
- 2001.12 Breast metastases to the liver
P.L. Pereira (Heilbronn/DE)

Discussion

10:15-12:00

Parallel Session**2002 Vanguard embolisations**

- 2002.1 Thermal ablation of vascular malformations
M.D. Darcy (St. Louis, MO/US)
- 2002.2 Gastric embolisation for weight loss
A. Arepally (Atlanta, GA/US)
- 2002.3 Embolisation of musculoskeletal pathology
Y. Okuno (Tokyo/JP)
- 2002.4 Embolisation of haemarthrosis
M.D. Darcy (St. Louis, MO/US)
- 2002.5 Embolisation for chronic haemorrhage from haemorrhoids
V. Vidal (Marseille/FR)
- 2002.6 Lymphangiographic approaches to lymphoceles
M. Itkin (Philadelphia, PA/US)
- 2002.7 The next phase in lymphatic interventions
M. Itkin (Philadelphia, PA/US)
- 2002.8 Thyroid embolisation for multi-goitre disease
O. Pellerin (Paris/FR)

Discussion

Faculty List

as per printing date - subject to change

Abada, H.T.	Abu Dhabi/AE	Kobeiter, H.	Créteil/FR
Ahrar, K.	Houston, TX/US	Krajina, A.	Hradec Králové/CZ
Angle, J.F.	Charlottesville, VA/US	Kroencke, T.J.	Augsburg/DE
Arai, Y.	Tokyo/JP	Lencioni, R.	Miami, FL/US
Arepally, A.	Atlanta, GA/US	Lewandowski, R.J.	Chicago, IL/US
Arslan, B.	Chicago, IL/US	Loffroy, R.	Dijon/FR
Belli, A.-M.	London/GB	Lohle, P.N.M.	Tilburg/NL
Benenati, J.F.	Miami, FL/US	Lönn, L.B.	Copenhagen/DK
Bhatia, S.	Davie, FL/US	Lopez, A.	Guildford/GB
Bilhim, T.	Lisbon/PT	Machan, L.	Vancouver/CA
Binkert, C.A.	Winterthur/CH	Malagari, K.	Athens/GR
Brountzos, E.	Athens/GR	Maleux, G.	Leuven/BE
Carette, M.-F.	Paris/FR	Mauri, G.	San Donato Milanese/IT
Cariati, M.	Milan/IT	McCafferty, I.	Birmingham/GB
Carnevale, F.C.	São Paulo/BR	McEniff, N.	Dublin/IE
Carrafiello, G.	Varese/IT	Meyer, B.C.	Hannover/DE
Chavan, A.	Oldenburg/DE	Miyayama, S.	Fukui/JP
Dake, M.D.	Stanford, CA/US	Morgan, R.A.	London/GB
Darcy, M.D.	St. Louis, MO/US	Niola, R.	Naples/IT
Das, R.	London/GB	Okuno, Y.	Tokyo/JP
de Baère, T.	Villejuif/FR	Orsi, F.	Milan/IT
Defreyne, L.	Ghent/BE	Osuga, K.	Osaka/JP
Denys, A.	Lausanne/CH	Pelage, J.-P.	Caen/FR
Do, Y.-S.	Seoul/KR	Pellerin, O.	Paris/FR
Fanelli, F.	Rome/IT	Pereira, P.L.	Heilbronn/DE
Funaki, B.S.	Chicago, IL/US	Pisco, J.M.	Lisbon/PT
Gaba, R.C.	Chicago, IL/US	Pollak, J.	New Haven, CT/US
Giroux, M.-F.	Montreal/CA	Ray, Jr., C.E.	Chicago, IL/US
Giurazza, F.	Rome/IT	Reekers, J.A.	Amsterdam/NL
Goffette, P.P.	Brussels/BE	Rousseau, H.	Toulouse/FR
Golzarian, J.	Minneapolis, MN/US	Rowlands, P.	Liverpool/GB
Grosso, M.	Cuneo/IT	Ruffino, M.A.	Turin/IT
Gwon, D.I.	Seoul/KR	Saad, W.E.	Ann Arbor, MI/US
Haage, P.	Wuppertal/DE	Sapoval, M.R.	Paris/FR
Hacking, N.	Southampton/GB	Savio, D.	Turin/IT
Hamady, M.S.	London/GB	Sone, M.	Tokyo/JP
Haskal, Z.J.	Charlottesville, VA/US	Spies, J.B.	Washington, DC/US
Hausegger, K.A.	Klagenfurt/AT	Szczerbo-Trojanowska, M.	Lublin/PL
Ierardi, A.M.	Varese/IT	Sze, D.Y.	Stanford, CA/US
Iezzi, R.	Rome/IT	Tanaka, T.	Kashihara/JP
Itkin, M.	Philadelphia, PA/US	Uberoi, R.	Oxford/GB
Jakobs, T.F.	Munich/DE	van Delden, O.M.	Amsterdam/NL
Jargielko, T.	Lublin/PL	Vidal, V.	Marseille/FR
Johnson, M.S.	Indianapolis, IN/US	Vorwerk, D.	Ingolstadt/DE
Kiyosue, H.	Yufu/JP	Wohlgemuth, W.A.	Regensburg/DE

General Information

Registration

Please note that your registration must be submitted and full payment needs to be received by the respective registration deadlines. Otherwise the respective next higher fee shall be due. Furthermore please be advised that incomplete registrations (not containing full name, e-mail and address) cannot be processed.

Registration Fees (Euro)

Early - until February 23, 2017 (23:59 CET)

Congress Registration	€590
CIRSE Member	€550
Resident/Nurse/Radiographer*/Student**	€325

Middle - until March 23, 2017 (23:59 CET)

Congress Registration	€790
CIRSE Member	€750
Resident/Nurse/Radiographer*/Student**	€385

Late - after March 23, 2017

Congress Registration	€840
CIRSE Member	€860
Resident/Nurse/Radiographer*/Student**	€420

* To be accompanied by a certificate, signed by the head of department.

** To be accompanied by a confirmation of student status at the time of congress, a one page CV and a copy of a valid photo ID.

Reduced CIRSE Member registration is only available for members of CIRSE (Cardiovascular and Interventional Radiological Society of Europe) in good standing.

Method of payment

Registration fees are to be paid in Euros (€) by: Bank Transfer or Credit Card (Visa or Master Card).

Subscription to ESIRonline

GEST Europe 2017 non-member scientific registrations include one-year access to ESIRonline (www.esir.org), the educational platform for interventional radiology, starting with the day of completed registration. CIRSE Members in good standing benefit from full access to ESIRonline.

Cancellation of congress registration

CIRSE GmbH offers all pre-registered participants the possibility to take out cancellation insurance with its partner „Europäische Reiseversicherung“. The insurance can only be booked during and until finalisation of the online registration process.

The refund of the participant's registration fee due to cancellation of the registration or the change of registration category is only possible with a valid insurance.

All requests must be made to „Europäische Reiseversicherung“ directly. Refunds will be given according to the terms and conditions of the „Europäische Reiseversicherung“. CIRSE GmbH shall not be responsible for any refunds of registration fees.

Name changes will be handled as a cancellation and new registration.

Additional information

All GEST Europe 2017 registrants will be able to print out an invoice of registration using their personal login details at www.gest2017.eu.

Invoices will be issued by: CIRSE Congress Research Education GmbH, Neutorgasse 9, 1010 Vienna, Austria

CME Credit Allowance

An application will be made to the EACCME® for CME accreditation of GEST Europe 2017.

Important Addresses

Congress Venue

Firenze Fiera Congress and Exhibition Centre
Palazzo dei Congressi
Piazza Adua 1
50123 Florence | Italy

CIRSE Central Office

Neutorgasse 9
1010 Vienna, Austria

Phone: +43 1 904 2003
Fax: +43 1 904 2003 30
www.gest2017.eu

E-mail Contacts

To obtain **general information** about the
GEST Europe 2017 meeting, please send an email to
office@esir.org

If you have any questions concerning **registration** for the
GEST Europe 2017 meeting, please send an email to
registration@esir.org

For information about the **scientific programme** of
GEST Europe 2017, please send an email to
scientific@esir.org

The CIRSE Foundation

The CIRSE Foundation is an independent, non-profit and tax exempt foundation. It promotes research and education in the field of minimally invasive, image guided therapies and, therefore, strengthens and complements the activities of CIRSE in this field.

For further information about the CIRSE Foundation and its activities please refer to the CIRSE website www.cirse.org.

Hotel Accommodation & Information


In cooperation with our travel partner Kuoni DMC, CIRSE has secured a great number of hotel rooms in Florence for the benefit of our congress participants. For further information about the official CIRSE hotels and room bookings, please refer to www.gest2017.eu.

If you have any questions, please do not hesitate to contact:

KUONI Congress

Contact: Martin Kotas
Via Andrea Doria, 33 20124 Milan | Italy

Phone: +420 296 300 422
Email: gest2017@ch.kuoni.com



Hotel Name	Category	Single Room (€)	Double room (€)	Travel Time Public transport	Travel Time Taxi
1 Hotel Executive	4*	185	195	walking distance	5 min.
2 Hotel Cerretani MGallery	4*	315	350	10 min.	5 min.
3 Hotel Croce Di Malta	4*	220	270	walking distance	5 min.
4 Hotel Palazzo Ricasoli	4*	180	210	15 min.	10 min.
5 Hotel Kraft	4*	230	250	10 min.	5 min.
6 Hotel Londra	4*	230	260	walking distance	
7 Grand Hotel Baglioni	4*	242	272	walking distance	
8 Hotel Adler Cavalieri	4*	219	240	walking distance	10 min.
9 Ambasciatori Hotel Florence	4*	230	255	walking distance	
10 Hotel De La Ville	4*	281	308	5 min.	3 min.
11 NH Firenze	4*	279	294	12 min.	10 min.
12 NH Porta Rossa	4*	355	375	10 min.	8 min.
13 NH Anglo American	4*	269	284	14 min.	12 min.
14 Hotel Albani Firenze	4*	265	295	walking distance	
15 Hotel Brunelleschi	4*	350	375	/	10min.
16 B4 Astoria Firenze	4*	200	220	walking distance	5 min.
17 Starhotels Michelangelo	4*	240	260	5 min.	5 min.
18 Hotel Cellai	4*	198	215	walking distance	
19 Grand Hotel Adriatico	4*	270	290	10 min.	5 min.

All rates are in Euros (€), per room, per night, including breakfast and VAT.

Room rates do not include city tax of €4.50 per night, per person. The city tax will be paid at the hotel upon check-in.

